Clinical trials: Radiation Safety, open to volunteers
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Whole Heart Radiotherapy for End-stage Heart Failure
End-stage heart failure (ESHF) causes recurrent hospitalizations, cardiac arrhythmias, and intolerance to standard HF therapies are common as the disease progresses.
- Conditions
- Heart Failure NYHA Class III, Heart Failure NYHA Class IV, End-stage Heart Failure, Heart Failure With Reduced Ejection Fraction
- Trial name
- ESHF-WHRT (NCT06299176)
- Testing
- Whole Heart Radiation Therapy
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Nasopharyngeal Carcinoma (NPC)
Hypofractionated Radiotherapy for Nasopharyngeal Carcinoma
The purpose of this study was to evaluate the efficacy and safety of large fractionation radiotherapy in nasopharyngeal carcinoma patients, and to analyze whether Hypofractionated radiotherapy is not inferior to conventional…
- Trial name
- NCT06796270
- Testing
- Hypofractionated radiotherapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- The Second Affiliated Hospital of Hainan Medical University
Lung Cancer, Extensive-stage Small-cell Lung Cancer
Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases
In patients with oligometastatic (1-5 lesions) extensive-stage small cell lung cancer, to explore the efficacy and safety of Durvalumab immunotherapy combined with chemotherapy followed by consolidation radiotherapy, to provide…
- Conditions
- Lung Cancer, Extensive-stage Small-cell Lung Cancer, Radiotherapy
- Trial name
- NCT05484583
- Testing
- Durvalumab + carboplatin/cisplatin + etoposide, Consolidation radiotherapy, Durvalumab
- Volunteers
- 58 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Brain Metastasis From Advanced HER2-negative Breast Cancer
Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis
A Prospective, multicenter, randomized controlled phase II study to evaluate the efficacy and safety of PD-L1 monoclonal antibody combined with vinorelbine + cyclophosphamide + capecitabine (VEX) metronomic chemotherapy and…
- Trial name
- NCT06839560
- Testing
- Adebrelimab+VEX Metronomic Chemotherapy+Concurrent Radiotherapy, Adebrelimab+VEX Metronomic Chemotherapy+Delayed Radiotherapy
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Keratoconus
Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus
Clinical trial to evaluate the safety and feasibility of corneal cross-linking in both eyes on the same day in subjects with keratoconus.
- Trial name
- NCT07629557
- Testing
- Riboflavin Ophthalmic Solutions, UV-A Irradiation System
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Glaukos Corporation
CRC (Colorectal Cancer)
Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM
Efficacy and safety of retlirafusp alfa combined with bevacizumab and chemotherapy with or without short-course radiotherapy in conversion therapy for advanced colorectal cancer liver metastases: an exploratory study.
- Trial name
- NCT07728019
- Testing
- SCRT, Retlirafusp alfa Injection, Bevacizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lung Cancer (NSCLC)
Percutaneous Pulsed Electric Field Ablation for Early-Stage NSCLC and Lung Oligometastases: A Safety and Efficacy Study
The goal of this observational study is to evaluate the performances of a percutaneous Pulsed Electrical Field (PEF) ablation to treat patients with primary early-stage lung cancer (NSCLC) or lung oligometastatic Tumors who are…
- Trial name
- NCT07799194
- Testing
- Pulsed Electric Field Ablation
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Energenx Medical LTD.
Breast Cancer Invasive
A Phase II Clinical Trial of Artificial Intelligence-assisted One-stop Radiotherapy for Breast Cancer After Breast-conserving Surgery
Background: Breast cancer became the most prevalent cancer globally in 2020, and post-surgery radiotherapy is crucial for most patients. Traditional radiotherapy is complex and time-consuming, affecting patient experience.
- Trial name
- BC-AIO (NCT06686459)
- Testing
- ALL-in-one radiotherapy, IMRT
- Where
- China
- Volunteers
- 860 people
- Sponsor
- Sun Yat-sen University
Radiotherapy, Immune Checkpoint Inhibitors (ICIs)
Real-world Study on the Efficacy, Safety, and Prognostic Factors of Immune Checkpoint Inhibitors Combined With Radiotherapy in Patients With Malignant Tumors: A Prospective Non-interventional Clinical Study
Currently, chemotherapy, targeted therapy, immunotherapy, and radiotherapy are the core treatment modalities for malignant tumors, with technologies advancing rapidly.
- Trial name
- NCT07665736
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sichuan University
AD - Alzheimer's Disease, MCI
A Phase I Study of [18F]Flortaucipir PET Imaging in Chinese Subjects: Safety, Pharmacokinetics, Biodistribution, Radiation Dosimetry, and Preliminary Diagnostic Efficacy
This is a non randomized, open-label Phase I study in Chinese participants. The goal of this clinical trial is to evaluate the safety and tolerability of a radioactive imaging agent called [18F]Flortaucipir Injection, which is…
- Trial name
- NCT07580703
- Testing
- [18F]Flortaucipir Injection
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eli Radiopharma
Rectal Cancer
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
Enrolled patients will receive upfront (week 1) short-course radiotherapy to gross pelvic disease (25Gy in 5fx) in combination with AB928 (150 mg orally, once daily as part of a continuous dose regimen).
- Trial name
- PANTHER (NCT05024097)
- Testing
- Etrumadenant (AB928), Radiation therapy, FOLFOX regimen
- Where
- 3 sites in United States
- Volunteers
- 43 people
- Sponsor
- Weill Medical College of Cornell University
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Lymphoma
Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden
Glofitamab has shown efficacy and safety in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and has been approved for marketing in China.
- Trial name
- GLOHRT-01 (NCT06867536)
- Testing
- Glofitamab + Obinutuzumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Liling Zhang
Lung Cancer (NSCLC), Neoadjuvant Immunotherapy
Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer
This multicenter retrospective real-world study aims to evaluate the safety, efficacy and survival outcomes of neoadjuvant/induction immunotherapy in patients with non-small cell lung cancer (NSCLC).
- Conditions
- Lung Cancer (NSCLC), Neoadjuvant Immunotherapy, Radiotherapy, Lung Surgery
- Trial name
- NCT06926179
- Testing
- neoadjuvant immunotherapy
- Where
- 4 sites in China
- Volunteers
- 500 people
- Sponsor
- Peking University Cancer Hospital & Institute
ESCC, TAS 102
TAS-102 Plus Radiotherapy in Elderly ESCC
This study is a single-arm, multicenter clinical trial evaluating the efficacy and safety of radiotherapy combined with TAS-102 monotherapy in elderly patients with locally advanced esophageal cancer.
- Conditions
- ESCC, TAS 102, Radiotherapy
- Trial name
- NCT07196345
- Testing
- TAS-102, Radiotherapy
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Qianfoshan Hospital
HCC - Hepatocellular Carcinoma
Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus
For HCC patients with PVTT who the researchers believe can benefit from radiotherapy combined with tislelizumab and anlotinib, informed consent forms will be signed, and then they will receive the study treatment and be followed…
- Trial name
- NCT07363512
- Testing
- Radiotherapy combined with tislelizumab and anlotinib
- Volunteers
- 27 people
- Sponsor
- Henan Cancer Hospital
Colorectal Cancer, Liver Metastasis
LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis
In recent years, growing evidences have demonstrated promising synergistic antitumor effects of radiotherapy combined with immunotherapy.
- Conditions
- Colorectal Cancer, Liver Metastasis, LDRT
- Trial name
- NCT06848465
- Testing
- Low Dose Radiotherapy, Short course Radiotherapy, XELOX
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Esophageal Squamous Cell Carcinoma (ESCC)
Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
This study aims to systematically evaluate the safety and efficacy of adalimumab combined with paclitaxel, carboplatin, and short-course radiotherapy in the neoadjuvant treatment of esophageal squamous cell carcinoma.
- Trial name
- ANCRE (NCT07595770)
- Testing
- • Adebrelimab and nab-paclitaxel, carboplatin in Combination With radiotherapy
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Endometrial Cancer, Endometrial Adenocarcinoma
Safety, Efficacy and Quality of Life After Adjuvant Hypofractionated Radiotherapy for Endometrial Cancer
Clinical experience with hypo fractionated radiotherapy to date has shown that it is a safe and effective way to treat many types of cancer.
- Trial name
- HEROS (NCT07871838)
- Testing
- Hypo fractionated RT
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Glioblastoma, Brain Tumor, Primary
Research on the Safety and Efficacy of Intraoperative Radiation Therapy in Malignant Cerebral Tumor
According to the latest national cancer statistics released by the National Cancer Center in February 2022, intracranial tumors account for about 60%-70% of the more than 3.5 million cancer patients, and the morbidity and…
- Conditions
- Glioblastoma, Brain Tumor, Primary, Brain Tumor - Metastatic
- Trial name
- NCT06929819
- Testing
- Intraoperative Radiation Therapy in Malignant Cerebral Tumor
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Low-to-intermediate-risk Prostate Carcinoma
Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy With SPACEOAR TM for Patients With Low-to-intermediate Risk Localized Prostate Cancer (DESAR-L)
A single institution with a single group, a phase II study, low- and medium-risk studies performed after biodegradable substance injection prostate cancer dosage increase.
- Trial name
- DESAR-L (NCT06461819)
- Testing
- Low- and medium-risk studies performed after biodegradable substance injection prostate cancer dose increase.
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Samsung Medical Center